Why the study?
Dichlorphenamide is approved for primary periodic paralysis but had not been studied in patients with Andersen-Tawil syndrome.
Does dichlorphenamide reduce paralytic attacks in a patient with Andersen-Tawil syndrome compared with acetazolamide?
Does dichlorphenamide reduce paralytic attacks in a patient with Andersen-Tawil syndrome compared with acetazolamide?
Dichlorphenamide may offer better control of paralytic attacks than acetazolamide in patients with Andersen-Tawil syndrome.
Answers are grounded in this paper and cite their sources.
Dichlorphenamide may reduce attacks versus acetazolamide in Andersen-Tawil syndrome; leaves open need for controlled trials before practice change.
Andersen-Tawil syndrome is a rare, autosomal dominant, multisystem disorder for which the majority of cases are caused by pathogenic variants in the KCNJ2 gene. The syndrome is characterized by the clinical triad of episodic paralysis, cardiac conduction abnormalities, and dysmorphic facial and skeletal features. Treatment of Andersen-Tawil syndrome is primarily focused on management of cardiac arrhythmias and preventive management of paralytic attacks. Dichlorphenamide is approved by the US Food and Drug Administration for use in primary periodic paralysis based on several randomized, controlled trials but has not been studied in patients with Andersen-Tawil syndrome. Here, we report a case of the syndrome caused by a de novo pathogenic variant in the KCNJ2 gene (c.95_98del). The paralytic attack rate for this patient was better controlled with dichlorphenamide compared with acetazolamide, further supporting the use of dichlorphenamide in patients with Andersen-Tawil syndrome.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: